Details

Autor(en) / Beteiligte

• Højgaard, Pil
• Ellegaard, Karen
• Nielsen, Sabrina Mai
• Christensen, Robin
• Guldberg‐Møller, Jørgen
• Ballegaard, Christine
• Dreyer, Lene
• Mease, Philip
• Wit, Maarten
• Skov, Lone
• Glintborg, Bente
• Bliddal, Henning
• Bartels, Else Marie
• Amris, Kirstine
• Kristensen, Lars Erik

Titel

Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study

Ist Teil von

• Arthritis care & research (2010), 2019-06, Vol.71 (6), p.798-810

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Wiley(RISS)

Beschreibungen/Notizen

• Objective To study the prognostic value of widespread pain and of musculoskeletal ultrasound (US) examination for subsequent treatment outcomes in patients with psoriatic arthritis (PsA). Methods An exploratory prospective cohort study enrolled patients with PsA initiating biologic or conventional synthetic disease‐modifying antirheumatic drugs in routine care. Clinical, US, and patient‐reported measures were collected at baseline and after 4 months. Widespread nonarthritic pain (WP) was defined as a Widespread Pain Index score of ≥4 with pain in ≥4 of 5 regions. PsA activity by US was defined as color Doppler (yes/no) in selected entheses, joints, or tendons. The main response criteria included the American College of Rheumatology 20% improvement, the Disease Activity in Psoriatic Arthritis 50% improvement, and minimal disease activity. The primary analyses were age‐ and sex‐adjusted logistic regression. Results WP was present in 24 of 69 included patients (35%) and was associated with worse patient‐reported and composite baseline measures, while US and other objective findings were similar to those in patients without WP. The odds of reaching minimal disease activity after 4 months were significantly greater for patients enrolled without WP (odds ratio 18.43 [95% confidence interval 1.51, 224.41]; P = 0.022), while WP did not impair other response measures. Patients with baseline color Doppler activity (n = 42 [61%]) had a worse objective PsA burden, but their chance of treatment response was comparable to those without color Doppler. Conclusion More than one‐third of patients with PsA presented with WP, which was associated with worse patient‐reported scores and failure to achieve minimal disease activity following conventional synthetic or biologic disease‐modifying antirheumatic drug therapy. PsA activity by color Doppler US had no influence on subsequent treatment response in this PsA cohort.